Results 71 to 80 of about 13,861 (164)

Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line

Frontiers in Cell and Developmental Biology, 2020
While topotecan (TPT) is a first- and second-line chemotherapeutic drug in treating lung cancer, the development of drug resistance in tumors still reserves as a major obstacle to chemotherapeutic success.
Zi-Ning Lei, Qiu-Xu Teng, Wei Zhang, Wei Zhang, Ying-Fang Fan, Ying-Fang Fan, Jing-Quan Wang, Chao-Yun Cai, Kimberly W. Lu, Kimberly W. Lu, Dong-Hua Yang, John N. D. Wurpel, Zhe-Sheng Chen   +12 more
doaj   +1 more source

Natural Products as Modulators of ABC Transporters in Breast Cancer

Phytotherapy Research, Volume 40, Issue 7, Page 4611-4637, July 2026.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan, Reyhaneh Farghadani, Ammu K. Radhakrishnan   +2 more
wiley   +1 more source

Topotecan and Ginkgolic Acid Inhibit the Expression and Transport Activity of Human Organic Anion Transporter 3 by Suppressing SUMOylation of the Transporter

Pharmaceutics
Organic anion transporter 3 (OAT3), expressed at the basolateral membrane of kidney proximal tubule cells, facilitates the elimination of numerous metabolites, environmental toxins, and clinically important drugs.
Zhou Yu, Guofeng You
doaj   +1 more source

Determination of Topotecan by ELISA.

Biological and Pharmaceutical Bulletin, 2001
A highly sensitive ELISA for the determination of (s)-9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) capable of measuring as low as 80 pg/ml was developed. Anti-topotecan antibody was obtained by immunizing rabbits with topotecan conjugated with bovine serum albumin using diazotized m-aminobenzoic acid as a cross-linker.
SAITA, Tetsuya, FUJITO, Hiroshi, MORI, Masato   +2 more
openaire   +3 more sources

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

BMC Cancer, 2007
Background A platinum doublet is the current standard treatment for good performance status patients with advanced non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status.
Kraft Andrew S, Meyer Mario L, Chaudhary Uzair, Garrett-Mayer Elizabeth, Green Mark R, Sherman Carol A, Beldner Matthew A, Montero Alberto J   +7 more
doaj   +1 more source

Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models

Neoplasia: An International Journal for Oncology Research, 2005
To investigate the cellular/molecular basis of the activity of a novel lipophilic camptothecin, gimatecan (ST1481), against slowly proliferating cells, we performed a comparative study of topotecan and gimatecan in human bladder cancer models (HT1376 and
Paola Ulivi, Wainer Zoli, Francesco Fabbri, Giovanni Brigliadori, Luca Ricotti, Anna Tesei, Marco Rosetti, Michelandrea De Cesare, Giovanni L. Beretta, Elisabetta Corna, Rosanna Supino, Franco Zunino   +11 more
doaj   +1 more source

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment

Diagnostics
Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor, and overall survival (OS) remains poor despite intensive efforts to develop new treatment strategies.
Laura Lambrecht, Paola Arnold, Jürgen Behr, Pontus Mertsch, Amanda Tufman, Diego Kauffmann-Guerrero   +5 more
doaj   +1 more source

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

OncoImmunology, 2018
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life.
S. Faraj, M. Bahri, S. Fougeray, A. El Roz, J. Fleurence, J. Véziers, M. D. Leclair, E. Thébaud, F. Paris, S. Birklé   +9 more
doaj   +1 more source

Topotecan [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2010
Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE, Yuanyuan ZHAO, Liping LIN, Guangchuan XU, Hongyun ZHAO, Yang ZHANG, Wei JIANG, Li ZHANG   +7 more
doaj